Iron parameters in 84 MDS patients enrolled in a deferasirox (Exjade®, ICL670) multicenter trial.

被引：0
|
作者：
List, Alan F.
Esposito, Jason
Decker, Jodie
Baer, Maria R.
Powell, Bayard
Steensma, David
Raza, Azra
Terebelo, Howard
Maciejewski, Jaroslaw
Goldberg, Stuart L.
Paley, Carole
机构：
[1] H Lee Moffitt Canc Ctr, Tampa, FL USA
[2] Nov Pharma Corp, E Hanover, NJ USA
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA
[5] Mayo Clin, Rochester, MN USA
[6] Univ Massachusetts, Worcester, MA 01605 USA
[7] Providence Canc Ctr, Southfield, MI USA
[8] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
[9] Hackensack Univ, Med Ctr, Hackensack, NJ USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4847
引用
收藏
页码：297B / 297B
页数：1
相关论文
共 50 条
  • [21] Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670)
    Di Tucci, Anna Angela
    Murru, Roberta
    Alberti, Daniele
    Rabault, Bertrand
    Deplano, Simona
    Angelucci, Emanuele
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 78 (06) : 540 - 542
  • [22] The once-daily oral chelator deferasirox (exjade®, ICL670) reduces iron overload in a murine model of juvenile hemochromatosis
    Nick, Hanspeter
    Allegrini, Peter
    Fozard, Lucy
    Junker, Ursula
    Rojkjaer, Lisa
    O'Reilly, Terrence
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 555 - 555
  • [23] Effect of iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion-dependent anemia
    Deugnier, Y.
    Turlin, B.
    Ropert-Bouchet, M.
    Rabault, B.
    Brissot, P.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S79 - S80
  • [24] Long-term safety and tolerability of the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload.
    Cappellini, M. D.
    Giardina, P.
    Porter, J.
    Coates, T.
    Della Porta, M. G.
    Siegel, J.
    Glimm, E.
    Ford, J.
    Cappellini, Maria Dominica
    BLOOD, 2006, 108 (11) : 501A - 501A
  • [25] Randomized phase II trial of deferasirox (Exjade•, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload
    Piga, Antonio
    Galanello, Renzo
    Forni, Gian Luca
    Cappellini, Maria Domenica
    Origa, Raffaella
    Zappu, Antonietta
    Donato, Guido
    Bordone, Elena
    Lavagetto, Antonella
    Zanaboni, Laura
    Sechaud, Rornain
    Hewson, Nicola
    Ford, John M.
    Opitz, Herbert
    Alberti, Daniele
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (07): : 873 - 880
  • [26] Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overloaded patients with β-thalassemia, treated with deferasirox (Exjade®, ICL670)
    Piga, A
    Fischer, R
    Harmatz, P
    St Pierre, TG
    Longo, F
    Fung, E
    Engelhardt, R
    Perrotta, S
    Galanello, R
    Capra, M
    Vichinsky, E
    Janka-Schaub, G
    Masera, G
    Cianciulli, P
    Coates, T
    Janssen, G
    Jeng, M
    Lai, ME
    Salles, G
    Cole, P
    Alberti, D
    Rosenkranz, G
    Opitz, H
    BLOOD, 2005, 106 (11) : 755A - 755A
  • [27] IRON CHELATION THERAPY WITH DEFERASIROX (ICL670) REDUCES SERUM FERRITIN (SF) AND LABILE PLASMA IRON (LPI) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    List, A. F.
    Baer, M. R.
    Steensma, D.
    Raza, A.
    Esposito, J.
    Virkus, J.
    Feigert, J.
    Besa, E.
    Paley, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 91 - 92
  • [28] Patient-reported outcomes of deferasirox (Exjade®, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis
    Vichinsky, Elliott
    Pakbaz, Zahra
    Onyekwere, Onyinye
    Porter, John
    Swerdlow, Paul
    Coates, Thomas
    Lane, Peter
    Files, Beatrice
    Mueller, Brigitta U.
    Coic, Lena
    Forni, Gian Luca
    Fischer, Roland
    Marks, Peter
    Rofail, Diana
    Abetz, Linda
    Baladi, Jean-Francois
    ACTA HAEMATOLOGICA, 2008, 119 (03) : 133 - 141
  • [29] Long-term treatment with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias
    Cappellini, Maria Domenica
    Vichinsky, Elliott
    Galanello, Renzo
    Piga, Antonio
    Williamson, Paul
    Porter, John B.
    BLOOD, 2007, 110 (11) : 816A - 816A
  • [30] Once-daily, oral chelation with deferasirox (Exjade®, ICL670) provides sustained protection from labile plasma iron in 2-thalassemia patients
    Daar, S.
    Taher, A.
    Pathare, A.
    Nick, H.
    Krahn, U.
    Hadler, D.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 513 - 514
12345